KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,095,554 | +19.3% | 944,502 | +11.5% | 0.00% | 0.0% |
| Q2 2023 | $7,624,854 | +651.4% | 847,206 | +556.3% | 0.00% | – |
| Q1 2023 | $1,014,687 | +25.7% | 129,095 | +8.1% | 0.00% | – |
| Q4 2022 | $807,327 | -84.0% | 119,427 | -65.6% | 0.00% | -100.0% |
| Q3 2022 | $5,032,000 | -6.8% | 346,822 | -36.8% | 0.00% | 0.0% |
| Q2 2022 | $5,402,000 | +172.6% | 548,981 | +308.3% | 0.00% | – |
| Q1 2022 | $1,982,000 | +761.7% | 134,470 | +672.5% | 0.00% | – |
| Q4 2021 | $230,000 | -80.8% | 17,406 | -74.6% | 0.00% | – |
| Q3 2021 | $1,197,000 | -65.5% | 68,562 | -52.6% | 0.00% | – |
| Q2 2021 | $3,468,000 | -42.1% | 144,748 | -37.9% | 0.00% | -100.0% |
| Q1 2021 | $5,991,000 | +27.1% | 233,211 | -6.1% | 0.00% | 0.0% |
| Q4 2020 | $4,715,000 | +559.4% | 248,300 | +165.6% | 0.00% | – |
| Q1 2020 | $715,000 | +505.9% | 93,503 | +817.2% | 0.00% | – |
| Q3 2019 | $118,000 | -74.7% | 10,194 | -51.6% | 0.00% | – |
| Q2 2019 | $467,000 | – | 21,072 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $25,679,000 | 12.37% |
| Vivo Capital, LLC | 1,618,296 | $30,731,000 | 1.37% |
| Opaleye Management Inc. | 470,203 | $8,929,000 | 1.17% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $7,383,000 | 0.92% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 177,433 | $3,369,000 | 0.92% |
| Ikarian Capital, LLC | 1,063,961 | $20,204,000 | 0.89% |
| Ghost Tree Capital, LLC | 200,000 | $3,798,000 | 0.85% |
| Logos Global Management LP | 490,000 | $9,305,000 | 0.80% |
| Eventide Asset Management | 1,680,000 | $31,903,000 | 0.49% |
| Affinity Asset Advisors, LLC | 45,000 | $855,000 | 0.45% |